Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2011 (2011), Article ID 683167, 14 pages
http://dx.doi.org/10.4061/2011/683167
Review Article

Malaria Treatment Policy Change and Implementation: The Case of Uganda

1Disease Prevention and Control Cluster: World Health Organization, Uganda Country Office, P.O. Box 24578, Kampala, Uganda
2Health Systems and Services Cluster: World Health Organization, Uganda Country Office, P.O. Box 24578, Kampala, Uganda
3National Malaria Control Program: Ministry of Health P.O. Box 7272, Kampala, Uganda
4World Health Organization, Uganda Country Office, P.O. Box 24578, Kampala, Uganda

Received 17 March 2011; Accepted 7 July 2011

Academic Editor: Ananias Escalante

Copyright © 2011 Miriam Nanyunja et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. E. Okello, W. Van Bortel, A. M. Byaruhanga et al., “Variation in malaria transmission intensity in seven sites throughout Uganda,” American Journal of Tropical Medicine and Hygiene, vol. 75, no. 2, pp. 219–225, 2006. View at Google Scholar · View at Scopus
  2. Roll Back Malaria Partnership, “Global Malaria Action Plan,” 2008, http://www.rollbackmalaria.org/gmap/0-5.html.
  3. Ministry of Health, “Uganda Malaria Control Policy,” 2000.
  4. M. R. Kamya, N. N. Bakyaita, A. O. Talisuna, W. M. Were, and S. G. Staedke, “Increasing antimalarial drug resistance in Uganda and revision of the national drug policy,” Tropical Medicine and International Health, vol. 7, no. 12, pp. 1031–1041, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. World Health Organization, Regional Office for Africa, Brazzaville, “Framework for Developing, Implementing, and Updating Antimalaria Treatment Policy: A Guide for Country Malaria Control Programmes,” 2003, http://afrolib.afro.who.int/documents/2003/english/framedrugp.pdf.
  6. World Health Organization, “Global report on antimalarial drug efficacy and drug resistance: 2000–2010,” 2010, http://www.searo.who.int/LinkFiles/Malaria_antimalarial_drug_efficacy10.pdf.
  7. A. O. Talisuna, A. Nalunkuma-Kazibwe, N. Bakyaita et al., “Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children,” Tropical Medicine and International Health, vol. 9, no. 2, pp. 222–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Bakyaita, G. Dorsey, A. Yeka et al., “Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda,” American Journal of Tropical Medicine and Hygiene, vol. 72, no. 5, pp. 573–580, 2005. View at Google Scholar · View at Scopus
  9. S. G. Staedke, A. Mpimbaza, M. R. Kamya, B. K. Nzarubara, G. Dorsey, and P. J. Rosenthal, “Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial,” The Lancet, vol. 364, no. 9449, pp. 1950–1957, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. Ministry of Health, Uganda, “National policy on malaria treatment 2005,” 2005, http://www.health.go.ug/mcp/NationalPolicyonMalariaTreatment(07_03_06).pdf.
  11. World Health Organization, “Position of WHO's Roll Back Malaria Department on malaria treatment policy,” 2003, http://www.who.int/malaria/publications/atoz/who_apt_position.pdf.
  12. A. Attaran, K. I. Barnes, C. Curtis et al., “WHO, the Global Fund, and medical malpractice in malaria treatment,” The Lancet, vol. 363, no. 9404, pp. 237–240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Fogg, F. Bajunirwe, P. Piola et al., “Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda,” American Journal of Tropical Medicine and Hygiene, vol. 71, no. 5, pp. 525–530, 2004. View at Google Scholar · View at Scopus
  14. S. G. Staedke, M. R. Kamya, G. Dorsey et al., “Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial,” The Lancet, vol. 358, no. 9279, pp. 368–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Dorsey, D. Njama, M. R. Kamya et al., “Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial,” The Lancet, vol. 360, no. 9350, pp. 2031–2038, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Ogwang, M. Engl, M. Vigl, H. Kollaritsch, G. Wiedermann, and W. H. Wernsdorfer, “Clinical and parasitological response of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in rural Uganda,” Wiener Klinische Wochenschrift, vol. 115, no. 3, pp. 45–49, 2003. View at Google Scholar · View at Scopus
  17. R. Ndyomugyenyi, P. Magnussen, and S. Clarke, “The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda,” Tropical Medicine and International Health, vol. 9, no. 1, pp. 47–52, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. A. F. Gasasira, G. Dorsey, B. Nzarubara et al., “Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda,” American Journal of Tropical Medicine and Hygiene, vol. 68, no. 2, pp. 127–132, 2003. View at Google Scholar · View at Scopus
  19. F. Checchi, P. Piola, C. Kosack et al., “Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda,” Tropical Medicine and International Health, vol. 9, no. 4, pp. 445–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Yeka, K. Banek, N. Bakyaita et al., “Artemesinin versus nonartemesinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda,” PLoS Medicine, vol. 2, no. 7, pp. 654–662, 2005. View at Google Scholar
  21. National Drug Authority, Uganda, “Human drug register for January 2011,” 2011, http://www.nda.or.ug/docs/Human_list.pdf.
  22. WHO; Promoting quality of medicines programme (PQM)—USAID, “Quality of antimalarials in Sub Saharan Africa,” 2010.
  23. F. K. Kato, “The malaria treatment policy change process in Uganda,” 2006. View at Google Scholar
  24. National Malaria Control Programme, Ministry of Health, Uganda Malaria Research Centre, and Malaria Consortium, “Assessing the availability of the first and second line antimalarials in selected health facilities in Uganda,” 2007. View at Google Scholar
  25. National Malaria Control Programme, “Analysis of malaria attendances according to AL dosage age groups,” 2007. View at Google Scholar
  26. D. Zurovac, J. Tibendarana, J. Nankabirwa, J. Ssekitooleko, A. Talisuna, and J. B. Rwakimari, “Evaluation of outpatient malaria case-management under artemether-lumefantrine treatment policy in Uganda,” 2007. View at Google Scholar
  27. L. Kapiriri and D. K. Martin, “The Global Fund Secretariat's suspension of funding to Uganda: how could this have been avoided?” Bulletin of the World Health Organization, vol. 84, no. 7, pp. 576–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. Ministry of Health, “Annual health sector performance reports for the financial year 2006/07,” 2007. View at Google Scholar
  29. J. A. Mulligan, R. Mandike, N. Palmer et al., “The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania,” Tropical Medicine and International Health, vol. 11, no. 4, pp. 452–461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. E. M. Malik, T. A. Mohamed, K. A. Elmardi et al., “From chloroquine to artemisinin-based combination therapy: the Sudanese experience,” Malaria Journal, vol. 5, article no. 65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Shretta, J. Omumbo, B. Rapuoda, and R. W. Snow, “Using evidence to change antimalarial drug policy in Kenya,” Tropical Medicine and International Health, vol. 5, no. 11, pp. 755–764, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Ringwald, T. Sukwa, L. K. Basco et al., “Monitoring of drug-resistant malaria in Africa,” The Lancet, vol. 360, no. 9336, pp. 875–876, 2002. View at Google Scholar · View at Scopus
  33. A. W. Holly, D. Durrheim, and R. Shretta, “The process of changing national malaria treatment policy: lessons from country-level studies,” Health Policy and Planning, vol. 19, no. 6, pp. 356–370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. G. M. Mubyazi and M. A. Gonzalez-Block, “Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug,” Malaria Journal, vol. 4, article number 51, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. H. A. Williams, D. Durrheim, and R. Shretta, “The process of changing national malaria treatment policy: lessons from country-level studies,” Health Policy and Planning, vol. 19, no. 6, pp. 356–370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Jowett, N. Miller, and N. Mnzava, “Malaria expenditure analysis. Tanzania case study. Report prepared for DFID-EA (Tanzania) and the Roll Back Malaria Initiative,” International Programme, Centre for Health Economics, University of York, York, UK, 2000.
  37. C. A. Goodman, P. G. Coleman, and A. J. Mills, “Changing the first line drug for malaria treatment—Cost-effectiveness analysis with highly uncertain inter-temporal trade-offs,” Health Economics, vol. 10, no. 8, pp. 731–749, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. W. K. Asenso-Okyere and J. A. Dzator, “Household cost of seeking malaria care. A retrospective study of two districts in Ghana,” Social Science and Medicine, vol. 45, no. 5, pp. 659–667, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. J. O. Nabyonga, F. Ssengooba, and S. Okuonzi, “Can donor aid for health be effective in a poor country? Assessment of prerequisites for aid effectiveness in Uganda,” The Pan African Medical Journal, vol. 3, p. 9, 2009. View at Google Scholar
  40. N. Oomman and M. Bernstein, Following the Funding for HIV/AIDS: A Comparative Analysis of the Funding Practices of PEPFAR, the Global Fund and World Bank MAP in Mozambique, Uganda and Zambia, Center for Global Development, Washington, Wash, USA, 2007.
  41. Kaiser Daily HIV/AIDS report, “HIV/AIDS/global financial crisis could harm HIV/AIDS funding,” Piot says, 2008, http://www.global healthreporting.org/article.asp?DR_ID=55258.
  42. S. A. Okuonzi and J. Macrae, “Whose policy is it anyway? International and national influences on health policy development in Uganda,” Health Policy and Planning, vol. 10, no. 2, pp. 122–132, 1995. View at Google Scholar · View at Scopus
  43. S. Abdulla, C. Goodman, P. Coleman, G. Mubyazi, N. Kikumbih, and T. Okorosobo, “The Costs, Effects and Cost-Effectiveness of Changing the First-Line Drug for the Treatment of Malaria in Tanzania,” Health Economics and Financing Programme (HEFP), LSHTM. Working Paper No. 01/00, 2000 http://www.dfid.gov.uk/r4d/PDF/Outputs/HealthEcFin_KP/WP01_00.pdf.
  44. J. A. Mulligan, R. Mandike, N. Palmer et al., “The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania,” Tropical Medicine and International Health, vol. 11, no. 4, pp. 452–461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. Uganda Bureau of Statistics, “National household Survey report,” 2005. View at Google Scholar
  46. B. Wasunna, D. Zurovac, C. A. Goodman, and R. W. Snow, “Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine,” Malaria Journal, vol. 7, article no. 29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. B. B. Kangwana, J. Njogu, B. Wasunna et al., “Short report: malaria drug shortages in kenya: a major failure to provide access to effective treatment,” American Journal of Tropical Medicine and Hygiene, vol. 80, no. 5, pp. 737–738, 2009. View at Google Scholar · View at Scopus